Literature DB >> 22872459

Treatment of invasive male breast cancer: a 40-year single-institution experience.

Icro Meattini1, L Livi, D Franceschini, C Saieva, V Scotti, D Casella, V Criscenti, I Zanna, F Meacci, E Gerlain, B Agresti, M Mangoni, F Paiar, G Simontacchi, D Greto, J Nori, S Bianchi, L Cataliotti, G Biti.   

Abstract

PURPOSE: We conducted a retrospective analysis to evaluate the management and outcome of invasive male breast cancer treated in a single-institution over a period of 40 years.
MATERIALS AND METHODS: We reviewed the clinical and pathological features of 60 male patients affected by breast carcinoma treated at our Radiotherapy Unit between 1971 and 2011. Tumours were classified according to histological type and the updated 2010 TNM classification of malignant tumours.
RESULTS: At a median follow-up of 8.9 [range, 0.6-20; standard deviation (SD), 4.98] years, 32 patients (53.3%) were alive and 16 patients died (26.7%) due to disease progression and 12 (20%) due to other causes. At univariate analysis for overall survival, pathological tumour size (p=0.031), histological subtype (p=0.013) and nodal status (p=0.006) emerged as significant predictors of death. At multivariate analysis, independent death predictors were advanced pathological tumour size (p=0.016), positive nodal status (p=0.003) and invasive cribriform histological type (p=0.0003).
CONCLUSIONS: In consideration of the rarity of the disease, many issues are still being debated, and future collaborative studies are required. However, our experience confirms the prognostic role of greater pathological tumour size and positive nodal status as unfavourable features for survival in male breast cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22872459     DOI: 10.1007/s11547-012-0867-x

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  34 in total

1.  The rising incidence of male breast cancer.

Authors:  Valerie Speirs; Abeer M Shaaban
Journal:  Breast Cancer Res Treat       Date:  2008-05-14       Impact factor: 4.872

2.  Adjuvant systemic therapy for male breast carcinoma.

Authors:  Sharon H Giordano; George H Perkins; Kristine Broglio; Sherry G Garcia; Lavinia P Middleton; Aman U Buzdar; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

Review 3.  Cancer of the breast in men.

Authors:  W L Donegan
Journal:  CA Cancer J Clin       Date:  1991 Nov-Dec       Impact factor: 508.702

4.  Sentinel lymph node biopsy in male breast cancer patients.

Authors:  A Goyal; K Horgan; M Kissin; C Yiangou; M Sibbering; M Lansdown; R G Newcombe; R E Mansel; U Chetty; P Ell; L Fallowfield; M Kissin
Journal:  Eur J Surg Oncol       Date:  2004-06       Impact factor: 4.424

5.  Breast carcinoma in men: a population-based study.

Authors:  Sharon H Giordano; Deborah S Cohen; Aman U Buzdar; George Perkins; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

6.  Is male breast cancer similar or different than female breast cancer?

Authors:  William F Anderson; Michelle D Althuis; Louise A Brinton; Susan S Devesa
Journal:  Breast Cancer Res Treat       Date:  2004-01       Impact factor: 4.872

7.  A 50-year experience of male breast cancer: is outcome changing?

Authors:  D B Gough; J H Donohue; M M Evans; P J Pernicone; L E Wold; J M Naessens; P C O'Brien
Journal:  Surg Oncol       Date:  1993-12       Impact factor: 3.279

8.  Current management of male breast cancer. A review of 104 cases.

Authors:  P I Borgen; G Y Wong; V Vlamis; C Potter; B Hoffmann; D W Kinne; M P Osborne; W M McKinnon
Journal:  Ann Surg       Date:  1992-05       Impact factor: 12.969

Review 9.  Breast cancer in men.

Authors:  W L Donegan; P N Redlich
Journal:  Surg Clin North Am       Date:  1996-04       Impact factor: 2.741

10.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

Authors:  N Bouzubar; K J Walker; K Griffiths; I O Ellis; C W Elston; J F Robertson; R W Blamey; R I Nicholson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.